Previous Close | 13.87 |
Open | 13.78 |
Bid | 5.44 x 900 |
Ask | 21.46 x 800 |
Day's Range | 13.42 - 14.20 |
52 Week Range | 5.20 - 21.02 |
Volume | |
Avg. Volume | 584,233 |
Market Cap | 599.844M |
Beta (5Y Monthly) | 0.83 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.86 |
Earnings Date | Nov 09, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 22.86 |
Subscribe to Yahoo Finance Plus to view Fair Value for VERA
The mean of analysts' price targets for Vera Therapeutics, Inc. (VERA) points to an 86.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Continued Progress in Clinical Trials and Strong Financial Position to Support Operations into Early 2026
Phase 2b open-label extension eGFR and proteinuria data expected in the first quarter of 2024; actively adding sites and enrolling pivotal Phase 3 ORIGIN 3 study of atacicept in IgANAnnounced analysis of Phase 2b ORIGIN study showing resolution of hematuria in the majority of patients, at the American Society of Nephrology Kidney Week 2023Strong balance sheet expected to fund operations to early 2026 BRISBANE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a la